SCHEMBL30830742

SCHEMBL30830742

Cc1c(NC2CC(c3ccc(C(=O)N4CCC5(CC4)CCN(c4ccc(C6CCC(=O)NC6=O)c(F)c4F)CC5)cc3)CN(C)C2)cnn(C)c1=O

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 9/20 0.38
▸ BRD9 Q9H8M2 3/20 0.38
▸ BPTF Q12830 2/20 0.38
▸ BRD1 O95696 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ BRPF1 P55201 1/20 0.38
▸ KAT2A Q92830 1/20 0.38
▸ BRD7 Q9NPI1 1/20 0.38
▸ BAZ2B Q9UIF8 1/20 0.38
▸ BRPF3 Q9ULD4 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.33
▸ CRBN Q96SW2 1/20 0.30
▸ IKZF3 Q9UKT9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830700 0.96 KAT2B (0.38) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30831008 0.96 KAT2B (0.38) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830563 0.93 KAT2B (0.47) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830620 0.91 KAT2B (0.46) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830976 0.91 KAT2B (0.46) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830648 0.91 KAT2B (0.46) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830810 0.91 KAT2B (0.38) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30831037 0.91 KAT2B (0.37) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830555 0.90 KAT2B (0.37) KAT2BBRD9BPTFBRD1ACHE
SCHEMBL30830890 0.90 KAT2B (0.39) KAT2BBRD9BPTFBRD1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback